Characterization of LDD-2633 as a Novel RET Kinase Inhibitor with Anti-Tumor Effects in Thyroid Cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Rearranged during transfection (RET) is a receptor tyrosine kinase implicated in thyroid cancers.
• Activating mutations or rearrangements in RET lead to uncontrolled cancer cell growth.
• Targeting RET activity is a key strategy in thyroid cancer treatment.

Purpose of the Study:

• To characterize the anti-tumor activity of the novel RET inhibitor LDD-2633.
• To evaluate LDD-2633's efficacy in medullary thyroid carcinoma models.
• To investigate LDD-2633's effects on the RET signaling pathway.

Main Methods:

• In vitro kinase inhibition assays for LDD-2633 against RET.
• Cell proliferation and apoptosis assays using TT thyroid carcinoma cells.
• Western blot analysis to assess RET signaling pathway modulation.
• In vivo xenograft studies in mice to evaluate anti-tumor efficacy.

Main Results:

• LDD-2633 demonstrated potent RET kinase inhibition (IC50 = 4.42 nM).
• LDD-2633 suppressed TT cell proliferation and induced apoptosis.
• LDD-2633 inhibited RET, Shc, and ERK1/2 phosphorylation.
• Oral LDD-2633 administration reduced xenograft tumor growth in a dose-dependent manner.

Conclusions:

• LDD-2633 exhibits significant anti-tumor activity against thyroid cancer cells in vitro and in vivo.
• LDD-2633 effectively targets the RET signaling pathway.
• LDD-2633 shows promise as a potential therapeutic agent for thyroid cancers.